These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 10594479)

  • 1. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study.
    Lim PO; Jung RT; MacDonald TM
    Br J Clin Pharmacol; 1999 Nov; 48(5):756-60. PubMed ID: 10594479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
    Mahmud A; Mahgoub M; Hall M; Feely J
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
    Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
    Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism.
    Catena C; Colussi G; Lapenna R; Nadalini E; Chiuch A; Gianfagna P; Sechi LA
    Hypertension; 2007 Nov; 50(5):911-8. PubMed ID: 17893375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone.
    Ori Y; Chagnac A; Korzets A; Zingerman B; Herman-Edelstein M; Bergman M; Gafter U; Salman H
    Nephrol Dial Transplant; 2013 Jul; 28(7):1787-93. PubMed ID: 23378418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RGS2 expression and aldosterone: renin ratio modulate response to drug therapy in hypertensive patients.
    Semplicini A; Strapazzon G; Papparella I; Sartori M; Realdi A; Macchini L; Calò LA; Ceolotto G
    J Hypertens; 2010 May; 28(5):1104-8. PubMed ID: 20375904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.
    Ghazi L; Dudenbostel T; Lin CP; Oparil S; Calhoun DA
    J Hypertens; 2016 May; 34(5):1005-10. PubMed ID: 26886564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO.
    Parthasarathy HK; Alhashmi K; McMahon AD; Struthers AD; McInnes GT; Ford I; Connell JM; MacDonald TM
    J Hypertens; 2010 Jan; 28(1):170-7. PubMed ID: 20009770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the aldosterone:renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study.
    Parthasarathy HK; Alhashmi K; McMahon AD; Struthers AD; Connell JM; McInnes GT; Ford I; MacDonald TM
    BMC Cardiovasc Disord; 2007 May; 7():14. PubMed ID: 17490489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension.
    Mahmud A; Feely J
    Am J Hypertens; 2005 Jan; 18(1):50-5. PubMed ID: 15691617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
    Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
    Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
    Williams B; MacDonald TM; Morant SV; Webb DJ; Sever P; McInnes GT; Ford I; Cruickshank JK; Caulfield MJ; Padmanabhan S; Mackenzie IS; Salsbury J; Brown MJ;
    Lancet Diabetes Endocrinol; 2018 Jun; 6(6):464-475. PubMed ID: 29655877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio.
    Hood SJ; Taylor KP; Ashby MJ; Brown MJ
    Circulation; 2007 Jul; 116(3):268-75. PubMed ID: 17606839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of low-dose spironolactone in subjects with resistant hypertension.
    Nishizaka MK; Zaman MA; Calhoun DA
    Am J Hypertens; 2003 Nov; 16(11 Pt 1):925-30. PubMed ID: 14573330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
    Sato A; Suzuki Y; Saruta T
    Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normokalemic hyperaldosteronism in patients with resistant hypertension.
    Benchetrit S; Bernheim J; Podjarny E
    Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum potassium levels predict blood pressure response to aldosterone antagonists in resistant hypertension.
    Shlomai G; Sella T; Sharabi Y; Leibowitz A; Grossman E
    Hypertens Res; 2014 Dec; 37(12):1037-41. PubMed ID: 24671013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
    White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
    Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)--study protocol.
    Vaclavik J; Sedlak R; Plachy M; Navratil K; Plasek J; Husar R; Kocianova E; Taborsky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Jun; 155(2):143-8. PubMed ID: 21804623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
    Gross E; Rothstein M; Dombek S; Juknis HI
    Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.